Syneron Medical Ltd, a leading global aesthetic device company, has announced that its new PicoWay® device has received CE Mark indication to treat tattoos of all types and colours and pigmented lesions on any skin type.
PicoWay is a new and innovative dual wavelength device, with 532nm and 1064nm wavelengths, which utilises Syneron’s proprietary PicoWay technology to deliver energy to the skin using pulses which are trillionths of a second, known as picosecond pulses.
Syneron will begin a staged launch of the PicoWay device in the international market during the third quarter of 2014 and anticipatesthat it will receive U.S. Food and Drug Administration (FDA) clearance for PicoWay by the end of 2014.
PicoWay’s high peak power and ultra-short pulse duration enable a unique mode of action which creates the strongest photo-mechanical impact to break up the tattoo ink or the pigmentation. This revolutionary PicoWay technology is integrated into a proven, reliable Candela® platform which ensures superior performance and low cost of ownership.
“Our investment in PicoWay’s research and development demonstrate Syneron’s commitment to develop technology that enables physicians to provide best-in-practice treatments for their patients,” stated Amit Meridor, CEO of Syneron.
“Since PicoWay has the shortest picosecond pulse duration and the highest peak power of any device on the market, we believe that fewer treatments will be needed and that the percentage clearance will be higher.”
For additional information click www.syneron-candela.co.uk or visit stand E10 at the CCR Expo on 10th and 11th October 2014.
